ClinicalTrials.gg
CompletedNCT05738850Updated Jul 1, 2024

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

A Phase 1 interventional study of ABBV-932 and Placebo in Generalized Anxiety Disorder (GAD) and Healthy Participants, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
107th of 234
104 · median 90
Started
2023
with 9 others
Phase 1
10 of 265
2 open now
Registered
213th of 265
by date
Lead sponsor
5 of 265
AbbVie

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 107th largest by enrollment of the 234 interventional ones that give a count, is one of 10 that started in 2023, is one of 10 in phase 1, and was the 213th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.

03

Conditions studied

  • Generalized Anxiety Disorder (GAD)
  • Healthy Participants

Keywords

  • Generalized Anxiety Disorder (GAD)
  • ABBV-932
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parts 1 and 2: Healthy individuals with body-mass index () >= 18.0 to \<= 32.0 kg/m2, rounded to the tenths decimal.
  • Part 3: Healthy Japanese, Han Chinese individuals with BMI >= 18.0 to \<= 30.0 kg/m2, rounded to the tenths decimal.
  • Condition of general good health based upon the results of a medical history, physical examination, vital signs, laboratory profile, neurological examination, and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History of any illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Part 1: ABBV-932

    Participants will receive ABBV-932 on Day 1 and followed for 30 days.

    Drug: ABBV-932

  • Placebo comparator
    Part 1: Placebo

    Participants will receive placebo on Day 1 and followed for 30 days.

    Drug: Placebo

  • Experimental
    Part 2: Sequence 1

    Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.

    Drug: ABBV-932

  • Experimental
    Part 2: Sequence 2

    Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.

    Drug: ABBV-932

  • Experimental
    Part 3: Japanese Participants: ABBV-932

    Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.

    Drug: ABBV-932

  • Placebo comparator
    Part 3: Japanese Participants: Placebo

    Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.

    Drug: Placebo

  • Experimental
    Part 3: Han-Chinese Participants: ABBV-932

    Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.

    Drug: ABBV-932

Interventions

  • Oral Capsule

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of ABBV-932

    Cmax of ABBV-932.

    Time frame: Up to approximately 5 days

  2. Time to Cmax (Tmax) of ABBV-932

    Tmax of ABBV-932.

    Time frame: Up to approximately 5 days

  3. Terminal Phase Elimination Rate Constant (Beta) of ABBV-932

    Terminal phase elimination rate constant (beta) of ABBV-932.

    Time frame: Up to approximately 5 days

  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-932

    Terminal phase elimination half-life of ABBV-932.

    Time frame: Up to approximately 5 days

  5. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932

    AUCt of ABBV-932.

    Time frame: Up to approximately 5 days

  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932

    AUCinf of ABBV-932.

    Time frame: Up to approximately 5 days

  7. Maximum Plasma Concentration (Cmax) of DCAR

    Cmax of DCAR.

    Time frame: Up to approximately 5 days

  8. Time to Cmax (Tmax) of DCAR

    Tmax of DCAR.

    Time frame: Up to approximately 5 days

  9. Terminal Phase Elimination Rate Constant (Beta) of DCAR

    Terminal phase elimination rate constant (beta) of DCAR.

    Time frame: Up to approximately 5 days

  10. Terminal Phase Elimination Half-Life (t1/2) of DCAR

    Terminal phase elimination half-life of DCAR.

    Time frame: Up to approximately 5 days

  11. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DCAR

    AUCt of DCAR.

    Time frame: Up to approximately 5 days

  12. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DCAR

    AUCinf of DCAR.

    Time frame: Up to approximately 5 days

  13. Maximum Plasma Concentration (Cmax) of DDCAR

    Cmax of DDCAR.

    Time frame: Up to approximately 5 days

  14. Time to Cmax (Tmax) of DDCAR

    Tmax of DDCAR.

    Time frame: Up to approximately 5 days

  15. Terminal Phase Elimination Rate Constant (Beta) of DDCAR

    Terminal phase elimination rate constant (beta) of DDCAR.

    Time frame: Up to approximately 5 days

  16. Terminal Phase Elimination Half-Life (t1/2) of DDCAR

    Terminal phase elimination half-life of DDCAR.

    Time frame: Up to approximately 5 days

  17. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DDCAR

    AUCt of DDCAR.

    Time frame: Up to approximately 5 days

  18. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DDCAR

    AUCinf of DDCAR.

    Time frame: Up to approximately 5 days

07

Study locations

2 sites
  • Anaheim Clinical Trials LLC /ID# 254178
    Anaheim, California 92801-2658, United States
  • Acpru /Id# 249639
    Grayslake, Illinois 60030, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in May 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Feb 22, 2023
StartActual
Feb 15, 2023
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05738850
Lead sponsor
AbbVie
Collaborators
Gedeon Richter Plc.
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Feb 15, 2023
Primary completion
May 31, 2024
Completion
May 31, 2024
Last update
Jul 1, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion